HighVista Strategies LLC Takes Position in Kura Oncology, Inc. (NASDAQ:KURA)

HighVista Strategies LLC purchased a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 16,764 shares of the company’s stock, valued at approximately $345,000.

Other institutional investors and hedge funds have also modified their holdings of the company. SG Americas Securities LLC purchased a new stake in Kura Oncology during the first quarter worth $110,000. Saxon Interests Inc. acquired a new stake in Kura Oncology in the 1st quarter valued at about $201,000. Entropy Technologies LP purchased a new position in Kura Oncology during the 1st quarter valued at about $218,000. Cape Investment Advisory Inc. purchased a new position in Kura Oncology during the 4th quarter valued at about $176,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Kura Oncology by 81.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 15,617 shares of the company’s stock worth $333,000 after purchasing an additional 7,027 shares during the last quarter.

Wall Street Analyst Weigh In

KURA has been the topic of several recent research reports. StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. Wedbush reaffirmed an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research note on Friday, August 9th. JMP Securities reissued a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. Finally, Stifel Nicolaus reduced their price objective on shares of Kura Oncology from $28.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.60.

Kura Oncology Trading Down 0.6 %

KURA stock opened at $20.95 on Monday. The company has a quick ratio of 14.94, a current ratio of 14.94 and a debt-to-equity ratio of 0.02. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -9.65 and a beta of 0.84. The business has a fifty day simple moving average of $20.25 and a 200-day simple moving average of $20.61. Kura Oncology, Inc. has a 52 week low of $7.41 and a 52 week high of $24.17.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.53) earnings per share. On average, equities research analysts expect that Kura Oncology, Inc. will post -2.45 EPS for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.